Fountoulakis, Andreas http://orcid.org/0000-0003-1341-0431
Souglakos, John
Vini, Louiza
Douridas, Gerasimos N.
Koumarianou, Anna
Kountourakis, Panteleimon
Agalianos, Christos
Alexandrou, Andreas
Dervenis, Christos
Gourtsoyianni, Sofia
Gouvas, Nikolaos
Kalogeridi, Maria-Angeliki
Levidou, Georgia
Liakakos, Theodoros
Sgouros, Joseph
Sgouros, Spiros N.
Triantopoulou, Charikleia
Xynos, Evangelos
Article History
Received: 23 September 2019
Accepted: 26 November 2019
First Online: 2 December 2019
Compliance with ethical standards
:
: Dr. KALOGERIDI reports non-financial support from Sanofi, outside the submitted work; Dr. XYNOS reports non-financial support from Johnson & Johnson, outside the submitted work; Dr. SOUGLAKOS reports grants from Amgen, grants and personal fees from Roche, grants and personal fees from Sanofi, personal fees from Servier, personal fees from MSD, personal fees from Merck Serono, personal fees from CellGene, outside the submitted work.
: No human participants or animals were involved during the execution of this research project.
: For this type of article, informed consent is not required.
: The study group considers adherence to these guidelines to be voluntary. The ultimate determination regarding their application is to be made by the physician in light of each patient’s individual circumstances. In view of the consulting and non-binding nature, these guidelines cannot form the basis for legal action or litigation for compliance or absence of compliance in the clinical practice setting, but can only be considered as general guidelines based on best available evidence for assistance in decision making. Any person seeking to apply or consult the evidence-based series is expected to use independent medical judgment in the context of individual clinical circumstances or seek out the supervision of a qualified clinician. HCGC-SG makes no representation or guarantees of any kind whatsoever regarding their content or use or application and disclaims any responsibility for their application or use in any way. In addition, these guidelines describe evaluations and administration of therapies in clinical practice; they cannot be assumed to apply to interventions performed in the context of clinical trials, given that such clinical studies are designed to test innovative management strategies in a disease for which better treatment is sorely needed. However, by reviewing and synthesising the latest literature, this practice guideline serves to identify questions for further research and the settings in which investigational therapy should be considered.